Cargando…

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data

SIMPLE SUMMARY: AS is an option for the initial management of selected patients with intermediate-risk PC. The proper way to predict which men will have an aggressive clinical course or indolent PC who would benefit from AS has not been unveiled. Genetics and MRI can help in the decision-making, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blas, Leandro, Shiota, Masaki, Eto, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454661/ https://www.ncbi.nlm.nih.gov/pubmed/36077698 http://dx.doi.org/10.3390/cancers14174161

Ejemplares similares

Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy
por: Shiota, Masaki, et al.
Publicado: (2022)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

The Role of Nuclear Receptors in Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2019)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
por: Chikamatsu, Sotaro, et al.
Publicado: (2022)

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
por: Blas, Leandro, et al.
Publicado: (2023)

Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
por: Shiota, Masaki, et al.
Publicado: (2016)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old
por: Blas, Leandro, et al.
Publicado: (2021)

Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016)

Active surveillance and focal therapy for low-intermediate risk prostate cancer
por: Klotz, Laurence
Publicado: (2015)

Active surveillance in intermediate risk prostate cancer: is it safe?
por: Henk, G. van der Poel, et al.
Publicado: (2016)

Active surveillance in intermediate risk prostate cancer: is it safe?
por: Krishnananthan, Nishanth, et al.
Publicado: (2016)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
por: Mukherjee, Subhabrata, et al.
Publicado: (2021)

Expanded criteria for active surveillance in prostate cancer: a review of the current data
por: Jones, Cameron, et al.
Publicado: (2018)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
por: Ushijima, Miho, et al.
Publicado: (2022)

Current status of active surveillance in prostate cancer
por: Chung, Mun Su, et al.
Publicado: (2016)

No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
por: Cyll, Karolina, et al.
Publicado: (2022)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
por: Hirata, Yu, et al.
Publicado: (2019)

Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
por: Beckmann, Kerri, et al.
Publicado: (2021)

Comparison of Outcomes of Active Surveillance in Intermediate-Risk Versus Low-Risk Localised Prostate Cancer Patients: A Systematic Review and Meta-Analysis
por: Mukherjee, Subhabrata, et al.
Publicado: (2023)

Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
por: Nishimura, Kazuo, et al.
Publicado: (2022)

Active Surveillance for Prostate Cancer: Past, Current, and Future Trends
por: de Vos, Ivo I., et al.
Publicado: (2023)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
por: Lo Greco, Maria Chiara, et al.
Publicado: (2023)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2020)

Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide
por: Kashiwagi, Eiji, et al.
Publicado: (2022)

Erratum to expanded criteria for active surveillance in prostate cancer: a review of the current data
por: Jones, Cameron, et al.
Publicado: (2018)

Active Surveillance for Localized Prostate Cancer – Current Practices and Recommendations
por: Wu, Jennifer N., et al.
Publicado: (2010)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Prostate cancer: a review of active surveillance
por: Lund, Lars, et al.
Publicado: (2014)

Active surveillance for low-risk prostate cancer
por: Klotz, Laurence
Publicado: (2012)

Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial
por: Moyad, Mark A, et al.
Publicado: (2014)

The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer?
por: Matsumoto, Takashi, et al.
Publicado: (2020)

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors
por: Shiota, Masaki, et al.
Publicado: (2023)

Influence of Active Surveillance on Gleason Score Upgrade and Prognosis in Low- and Favorable Intermediate-Risk Prostate Cancer
por: Hu, Xuanhan, et al.
Publicado: (2022)

Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review
por: Lawrentschuk, Nathan, et al.
Publicado: (2010)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gjpbpkp5i06f11i8jp1dhqdp6b